• Anti-InfectiveClosed to Enrollment

  Inhaled Levofloxacin (MP-376) pediatric safety study , protocol number MPEX 206

  This study took place at multiple care centers across the U.S. It looked at the safety and tolerability of MP-376 Inhalation Solution, as well as how the body processes the drug, in children with CF.

  • Age:

    6 Years to 16 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 95%

  • Number of Visits:

    6

  • Length of Participation:

    35 days

• Anti-InfectiveCompleted with Results

  Levofloxacin Inhalation Solution (Aeroquin™) compared to TOBI® in people with Cystic Fibrosis , protocol number MPEX 209

  This study looked at the safety and effectiveness of levofloxacin inhalation solution (AEROQUIN™), compared to tobramycin solution for inhalation (TIS in people with CF who had chronic Pseudomonas aeruginosa lung infection.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 85%

  • Number of Visits:

    10

  • Length of Participation:

    6 months

• Anti-InfectiveCompleted with Results

  Levofloxacin Inhalation Solution (Aeroquin™) compared to placebo in people with Cystic Fibrosis , protocol number MPEX 207

  This phase 3 study evaluated the safety and effectiveness of the aerosolized form of the antibiotic, levofloxacin, (AEROQUIN™) in people with CF.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 85%

  • Number of Visits:

    6

  • Length of Participation:

    2 months

• Anti-InfectiveCompleted with Results

  Inhaled Levofloxacin (MP-376) in CF Patients with P. aeruginosa (Phase 2 Study) , protocol number MPEX-204

  This phase 2 study evaluated the safety and effectiveness of a new inhaled antibiotic (MP-376 - a solution of levofloxacin) to control chronic pulmonary infections due to Pseudomonas aeruginosa in people with CF.

  • Age:

    16 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 75%

  • Number of Visits:

    6

  • Length of Participation:

    14 weeks

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.